Pulmatrix (NASDAQ:PULM) Announces Quarterly Earnings Results

Pulmatrix (NASDAQ:PULM) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.25) earnings per share for the quarter, FiscalAI reports.

Pulmatrix Price Performance

Shares of NASDAQ PULM traded up $0.05 during mid-day trading on Friday, hitting $2.96. The company had a trading volume of 7,989 shares, compared to its average volume of 14,953. Pulmatrix has a 12 month low of $2.15 and a 12 month high of $9.37. The stock has a market cap of $10.79 million, a price-to-earnings ratio of -1.74 and a beta of 1.72. The firm’s 50 day simple moving average is $2.52 and its two-hundred day simple moving average is $3.95.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Pulmatrix presently has an average rating of “Sell”.

Institutional Investors Weigh In On Pulmatrix

A number of hedge funds have recently added to or reduced their stakes in PULM. SBI Securities Co. Ltd. lifted its stake in shares of Pulmatrix by 15.7% in the 2nd quarter. SBI Securities Co. Ltd. now owns 60,565 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 8,208 shares during the period. Dimensional Fund Advisors LP bought a new stake in Pulmatrix during the third quarter worth approximately $52,000. Finally, DRW Securities LLC acquired a new stake in Pulmatrix in the fourth quarter worth approximately $46,000. 11.84% of the stock is currently owned by institutional investors.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).